USANA Health Sciences, Inc. (NYSE: USNA) announced its preliminary third‑quarter 2025 results on October 10, 2025. The company reported net sales of $214 million, up 7% from $200 million in the same quarter a year earlier, while an effective tax rate of 471% pushed net earnings to a loss of $6.5 million and diluted earnings per share to –$0.36.
Earnings from operations were expected to be $1.2 million, a sharp decline from $15.6 million in Q3 2024. Adjusted diluted EPS was –$0.15 and adjusted EBITDA stood at $13.8 million, reflecting the impact of one‑time tax and integration costs associated with the Hiya acquisition.
The preliminary results highlight softer sales and lower Brand Partner productivity during the rollout of the enhanced compensation plan, and a softer performance from Hiya’s direct‑to‑consumer channel. The company reiterated that it anticipates Q3 net sales of $214 million and that final results will be released after the market close on October 21, 2025.
These figures represent a significant decline in profitability for the quarter, underscoring the short‑term impact of strategic investments while the company remains focused on long-term growth through its omnichannel transformation.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.